Drug Profile
BioLexa - Hoth Therapeutics
Alternative Names: BioLexa™; Gentamicin/Diethylenetriaminepentaacetic acidLatest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator University of Cincinnati
- Developer Hoth Therapeutics; University of Cincinnati
- Class Antibacterials; Skin disorder therapies
- Mechanism of Action Chelating agents; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Atopic dermatitis
- No development reported Bacterial infections; Wounds
Most Recent Events
- 06 Sep 2023 Final efficacy data from a phase I trial in atopic dermatitis released by Hoth Therapeutics
- 28 Aug 2023 No recent reports of development identified for preclinical development in Wounds in USA (Topical, Lotion)
- 31 Oct 2022 Efficacy and adverse events data from phase Ib trial in Atopic dermatitis released by Hoth Therapeutics